title: Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
abstract: OBJECTIVE
  Controlled ileal release budesonide and slow release mesalazine are both used to treat mild to moderate active Crohn's disease, although data show that budesonide is more effective in inducing remission. When comparing different treatment options, the effects of agents on health-related quality of life must be considered as well as efficacy. In this study, we sought to compare the effects of budesonide and mesalazine on the health-related quality of life of patients with active Crohn's disease.
  
  
  METHODS
  The study included 182 patients with Crohn's Disease Activity Index scores between 200 and 400. Patients were randomized in a double blind, double dummy, multicenter study to receive 9 mg of budesonide, once daily (n = 93), or 2 g of mesalazine, b.i.d. (n = 89), for 16 wk. Quality of life was assessed at baseline and after 2, 4, 8, 12, and 16 wk of treatment using the Psychological General Well-Being index. In addition, a physician's global evaluation was used to assess how symptoms affected patients' normal activities.
  
  
  RESULTS
  Patients treated with budesonide experienced significantly greater improvement in Psychological General Well-Being scores than the group treated with mesalazine after 2, 8, 12, and 16 wk. All components of this index showed greater improvements in the budesonide-treated group than in the mesalazine group at 12 and 16 wk. The physician's global evaluation showed significantly greater improvements in the budesonide group than in the mesalazine group at all visits.
  
  
  CONCLUSIONS
  Budesonide (9 mg once daily) improves health-related quality of life to a greater extent than mesalazine (2 g b.i.d.) in patients with mild to moderate active Crohn's disease.
authors.affiliation: Department of Gastroenterology C, Herlev Hospital, Copenhagen, Denmark.
authors.forename: Ole O
authors.initials: OO
authors.lastname: Thomsen
authors.forename: Antoine
authors.initials: A
authors.lastname: Cortot
authors.forename: Derek
authors.initials: D
authors.lastname: Jewell
authors.forename: John P
authors.initials: JP
authors.lastname: Wright
authors.forename: Trevor
authors.initials: T
authors.lastname: Winter
authors.forename: Fernando T
authors.initials: FT
authors.lastname: Veloso
authors.forename: Morten
authors.initials: M
authors.lastname: Vatn
authors.forename: Tore
authors.initials: T
authors.lastname: Persson
authors.forename: Eva
authors.initials: E
authors.lastname: Pettersson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine; D019819:Budesonide